Phase II and III Clinical Trials of Toremifene for Metastatic Breast Cancer

ONCOLOGY

Volumn 12, Issue 3 SUPPL. 5, 1998, Pages 9-13

  Vogel, Charles L ^a,b  

^a Columbia Cancer Res Netwk Florida ^*  (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001777491     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Hamm JT, Tormey DC, Kohler PC, et al: Phase I study of toremifene in patients with advanced cancer. J Clin Oncol 9(11):2036-2041, 1991
2. Hamm JT: Phase I and II studies of toremifene. Oncology 11(5;suppl 4):19-22, 1997.
3. Wiebe VJ, Benz CC, Shemano I, et al: Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer. Cancer Chemother Pharmacol 25(4):247-251, 1990.
4. Tominaga T, Abe O, Izuo M, et al: A phase I study of toremifene. Breast Cancer Res Treat 16(suppl):S27-S29, 1990.
5. Kivinen S, Maenpaa J: Effect of toremifene on clinical chemistry, hematology and hormone levels at different doses in healthy postmenopausal women: Phase I study. J Steroid Biochem Mol Biol 36(3):217-220, 1990.
6. Valavaara R: Phase II trials with toremifene in advanced breast cancer: A review. Breast Cancer Res Treat 16(suppl):S31-S35, 1990.
7. Hietanen T, Hakala T, Baltina D, et al: Open phase II study of high-dose toremifene as first-line therapy for advanced breast cancer. Oncology 11(6;suppl 4):37-40, 1997
8. Gershanovich M, Hayes DF, Ellmén J, et al: High-dose toremifene vs tamoxifen in postmenopausal advanced breast cancer. Oncology 11 (6,suppl 4):29-36, 1997.
9. Kangas L: Introduction to torernifene. Breast Cancer Res Treat 16(suppl):S3-S7, 1990.
10. Ebbs SR, Roberts JV, Baum M: Alternative mechanism of action of "anti-oestrogens" in breast cancer (letter). Lancet 2:621, 1987.
11. Perry JJ, Berry DA, Weiss RB, et al: High-dose toremifene for estrogen and progesterone receptor negative metastatic breast cancer: A phase II trial of CALGB. Breast Cancer Res Treat 36(1):35-40, 1995.
12. Valavaara R: Reliability of estrogen receptors in predicting response to antiestrogens. Oncology 11(6;suppl 4):14-18, 1997.
13. Modig H, Borgstrom S, Nilsson I, et al: Phase II clinical study of high-dose toremifene in patients with metastatic breast cancer: Preliminary communication. J Steroid Biochem Mol Biol 36(3):235-236, 1990.
14. Vogel CL, Shemano I, Schoenfelder J. et al: Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J Clin Oncol 11(2):345-350, 1993.
15. Pyrhonen S, Valavaara R, Vuormen J, et al: High-dose toremifene in advanced breast cancer resistant to or relapsed during tamoxifen treatment. Breast Cancer Res Treat 29(3):223-228, 1994.
16. Asaishi K, Tominaga T, Abe O: Efficacy and safety of high-dose NK 622 (toremifene citrate) in tamoxifen failed patients with breast cancer. Gan To Kagaku Ryoho 20(1):91-99, 1993.
17. Robertson JFR, Willsher P, Cheung KL, et al: The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer (abstract). Proc Am Soc Clin Oncol 15:101a, 1996.
18. Howell A, Mackintosh J, Jones M, et al: The definition of the "no change" category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol 24:1567-1572, 1988.
19. Robertson JF, Williams MR, Todd J, et al: Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur J Cancer Clin Oncol 25(3):469-475, 1989.
20. Fornander T, Cedermark B, Mattsson A, et al: Adjuvant tamoxifen therapy for early stage breast cancer: Occurrence of new primary cancers. Lancet 2:117-120, 1989.
21. Williams GM, Jeffrey AM: Safety assessment of tamoxifen and toremifene. Oncology 11(6;suppl 4):41:47, 1997.
22. Hayes DF, van Zyl JA, Hacking A, et al: Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13:2556-2566, 1995.
23. Gershanovich M, Garin A, Baltina D, et al. Eastern European Study Group: A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Breast Cancer Res Treat, 1997 (in press).
24. Pyrhonen S, Valavaara R, Modig H: Comparison of toremifene and tamoxifen in postmenopausal patients with advanced breast cancer: A randomized double-blind, the Nordic phase III study. Br J Cancer 76(2):270-277, 1997.
25. Gams R: Phase III trials of toremifene vs tamoxifen. Oncology 11(6;suppl 4):23-28, 1997.
26. Brooks SC, Saunders DE, Singhakowinta A, et al: Relation of tumor content of estrogen and progesterone receptors with response of patient to endocrine therapy. Cancer 46:2775-2778, 1980.